Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

AIMAZ AFROUGH

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1477964518
CMS profile
4218677
Location
DALLAS, TX

General Payments · PY2018–2024

$12,820.61

  • Reported across 153 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$9,867.90

12 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $3,484.01 3
E.R. Squibb & Sons, L.L.C. $2,422.00 1
PFIZER INC. $2,200.00 1
Janssen Scientific Affairs, LLC $1,254.62 2
Janssen Biotech, Inc. $230.01 3
SANOFI-AVENTIS U.S. LLC $173.69 1
Legend Biotech USA Inc. $103.57 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $869.54 58
PY2019 $1,087.27 59
PY2020 $215.44 11
PY2021 $8.25 1
PY2022 $450.39 7
PY2023 $321.82 5
PY2024 $9,867.90 12

Payment records · PY2024 (12)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
E.R. Squibb & Sons, L.L.C. $2,422.00 01/25/2024 Consulting Fee Undisputed 01/23/2026 1101377966 CMS
GENZYME CORPORATION $3,295.00 07/10/2024 Consulting Fee Undisputed 01/23/2026 1139579218 CMS
GENZYME CORPORATION $167.17 07/11/2024 Food and Beverage Undisputed 01/23/2026 1139579214 CMS
GENZYME CORPORATION $21.84 08/23/2024 Travel and Lodging Undisputed 01/23/2026 1139579216 CMS
Janssen Biotech, Inc. $77.84 09/25/2024 Food and Beverage Undisputed 01/23/2026 1078707811 CMS
Janssen Biotech, Inc. $57.67 12/08/2024 Food and Beverage Undisputed 01/23/2026 1078706244 CMS
Janssen Biotech, Inc. $94.50 12/09/2024 Food and Beverage Undisputed 01/23/2026 1078704456 CMS
Janssen Scientific Affairs, LLC $104.62 02/21/2024 Food and Beverage Undisputed 01/23/2026 1078859557 CMS
Janssen Scientific Affairs, LLC $1,150.00 10/22/2024 Consulting Fee Undisputed 01/23/2026 1078859414 CMS
Legend Biotech USA Inc. $103.57 12/07/2024 Food and Beverage Undisputed 01/23/2026 1131694186 CMS
PFIZER INC. $2,200.00 10/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1132064382 CMS
SANOFI-AVENTIS U.S. LLC $173.69 02/23/2024 Food and Beverage Undisputed 01/23/2026 1139579104 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.